Katelyn is a reporter with CNET covering artificial intelligence, including chatbots, image and video generators. Her work explores how new AI technology is infiltrating our lives, shaping the content ...

Detailed price information for Jpmorgan US Value Active ETF (JAVA-T) from The Globe and Mail including charting and trades.

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this ...

Holding a high-yield dividend portfolio in a taxable account at the 24% federal bracket means writing the IRS a $14,400 check every year on $60,000 of income that should have been yours. It repeats ...

We may receive commissions from some links to products on this page. Promotions are subject to availability and retailer terms. High-yield savings and money market accounts both have variable interest ...

Donald Trump is on TikTok doing his morning routine. “Get ready with me for a big day 💄🇺🇸,” reads the caption, as the president holds a makeup brush to his cheek. The scene is a still, ostensibly a ...

Most banks don't charge, but some have early closeout fees Jessica Gibson is a content update editor and writer for Investopedia. She has over 10 years of experience in digital publishing and three ...

The average traditional savings account is paying just 0.38% in interest right now, according to the latest data from the FDIC — a rate that has actually dipped since last month. For anyone parking a ...

Threat actors are evading phishing detection in campaigns targeting Microsoft accounts by abusing the no-code app-building platform Bubble to generate and host malicious web apps. Because the web app ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Generate:Biomedicines has earmarked $300 million of its IPO funds to complete a pair of phase 3 asthma trials for its anti-TSLP antibody GB-0895. (Fabrice Cabaud/Stock/Getty Images Plus) ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...